<div id="readability-page-1"><p>Addus HomeCare Corporation (NASDAQ:ADUS - Get Free Report) EVP Michael Wattenbarger sold 592 shares of the firm's stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $107.35, for a total transaction of $63,551.20. Following the transaction, the executive vice president directly owned 9,744 shares of the company's stock, valued at approximately $1,046,018.40. This represents a 5.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website.</p><div><p><span></span><span>Get <strong>Addus HomeCare</strong> alerts:</span></p></div><h2>Addus HomeCare Stock Performance</h2><p>ADUS stock traded down $3.58 during midday trading on Thursday, reaching $104.02. The company had a trading volume of 269,378 shares, compared to its average volume of 239,147. Addus HomeCare Corporation has a fifty-two week low of $88.96 and a fifty-two week high of $124.43. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.11. The stock has a 50 day moving average price of $109.57 and a 200 day moving average price of $113.08. The firm has a market capitalization of $1.92 billion, a PE ratio of 19.97, a P/E/G ratio of 1.26 and a beta of 0.91. </p><h2>Addus HomeCare News Roundup</h2><p>Here are the key news stories impacting Addus HomeCare this week:</p><ul>   <li><span>Positive Sentiment: </span>Q4 earnings/earnings call emphasized continued revenue growth, margin-leverage opportunities and an M&amp;A-driven growth strategy for 2026 — supports longer‑term earnings upside. <i></i><span>Addus HomeCare Earnings Call Highlights Growth And Scale</span></li>    <li><span>Positive Sentiment: </span>Stephens trimmed its price target from $140 to $135 but kept an &#34;overweight&#34; rating — the new target implies meaningful upside from current levels, indicating analyst confidence in the company’s outlook despite the cut. <i></i><span>Stephens price target note</span></li>    <li><span>Neutral Sentiment: </span>Addus will participate in the Raymond James Institutional Investors Conference (investor visibility event; typically neutral but can aid liquidity/coverage). <i></i><span>Conference participation</span></li>    <li><span>Neutral Sentiment: </span>Some published short‑interest data in the feed shows zero shares (data glitch/inconsistent reporting across sources) — treat those specific zero figures with caution. <i></i><span>MarketBeat ADUS page</span></li>    <li><span>Negative Sentiment: </span>Significant insider selling over Feb. 24–25: CEO R. Dirk Allison sold two blocks (4,988 and 2,364 shares) and multiple senior EVPs sold smaller blocks across the two days — coordinated insider sales can pressure sentiment even if individual sales are routine and pre‑planned. See CEO filing. <i></i><span>CEO insider-sale SEC filing</span></li>    <li><span>Negative Sentiment: </span>Short interest rose earlier in February (as of Feb. 13 there were ~1.15M shares short, ~6.5% of shares outstanding and ~4.6 days‑to‑cover) — elevated short activity can amplify downward price moves. <i></i><span>Short interest data</span></li> </ul><h2>Analyst Upgrades and Downgrades</h2><p>Several analysts have issued reports on ADUS shares. Truist Financial  set a $135.00 price target on shares of Addus HomeCare and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, January 7th. Stephens cut their price objective on Addus HomeCare from $140.00 to $135.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday. Royal Bank Of Canada  reissued an &#34;outperform&#34; rating and issued a $139.00 target price on shares of Addus HomeCare in a report on Wednesday. BMO Capital Markets started coverage on shares of Addus HomeCare in a report on Thursday, November 13th. They set a &#34;market perform&#34; rating and a $120.00 price objective on the stock. Finally, TD Cowen  reiterated a &#34;buy&#34; rating on shares of Addus HomeCare in a research report on Wednesday, November 5th. One equities research analyst  has rated the stock with a Strong Buy rating, seven have issued  a Buy rating, two have assigned  a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat.com, Addus HomeCare presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $134.33.</p><p><b>View Our Latest Stock Analysis on Addus HomeCare</b></p><h2>Institutional Trading of Addus HomeCare</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of the stock. Global Retirement Partners LLC raised its holdings in  Addus HomeCare by 395.7% during the 4th quarter. Global Retirement Partners LLC now owns 233 shares of the company's stock worth $25,000 after purchasing an additional 186 shares during the last quarter.  Larson Financial Group LLC increased its position in shares of  Addus HomeCare by 133.3% during the third quarter. Larson Financial Group LLC now owns 238 shares of the company's stock worth $28,000 after buying an additional 136 shares during the period.  Acumen Wealth Advisors LLC acquired a new stake in shares of  Addus HomeCare during the fourth quarter worth $29,000.  Private Trust Co. NA raised its stake in  Addus HomeCare by 65.5% during the fourth quarter. Private Trust Co. NA now owns 283 shares of the company's stock worth $30,000 after buying an additional 112 shares during the last quarter.  Finally, Arax Advisory Partners lifted its holdings in  Addus HomeCare by 95.8% in the fourth quarter. Arax Advisory Partners now owns 280 shares of the company's stock valued at $30,000 after buying an additional 137 shares during the period. Institutional investors own  95.35% of the company's stock. </p><h2>Addus HomeCare Company Profile</h2> (Get Free Report)<p>Addus HomeCare <span>NASDAQ: ADUS<span></span></span> is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients' independence and quality of life.  </p><p>The company's core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.</p><h2>Read More</h2><ul><li>Five stocks we like better than Addus HomeCare</li><li>Unlocked: Elon Musk’s Next Big IPO</li><li>REVEALED: Something Big Happening Behind White House Doors</li><li>This makes me furious</li><li>The free stock picks nobody’s talking about</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURVUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURVUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Addus HomeCare Right Now?</h2><p>Before you consider Addus HomeCare, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Addus HomeCare wasn't on the list.</p><p>While Addus HomeCare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ADUS

<p>Michael Wattenbarger, EVP of Addus HomeCare (NASDAQ:ADUS), sold 592 shares at $107.35 each on February 24, totaling $63,551.20. Post-sale, he holds 9,744 shares valued at approximately $1,046,018.40, marking a 5.73% decrease in his ownership. The transaction was disclosed to the SEC. Meanwhile, ADUS stock fell to $104.02, with analysts maintaining a generally positive outlook despite some insider selling and increased short interest. Price targets from analysts range from $120 to $140, reflecting confidence in the company's growth potential.</p>

Michael Wattenbarger Sells 592 Shares of Addus HomeCare (NASDAQ:ADUS) Stock